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Abstract
Background: Although recruiting newborns is ethically challenging, clinical trials remain essential to improve
neonatal care. There is a lack of empirical data on the parental perspectives following participation of their neonate
in a clinical trial, especially at long term. The objective of this study is to assess experiences and emotions of
parents, long term after trial participation in an interventional drug trial.
Methods: Parents of former participants of five neonatal interventional drug trials were surveyed at long term (3–
13 years ago) after participation. The survey assessed parental contentment with trial participation, perceived
influence of the trial on care and health, emotional consequences of participation, and awareness of typical clinical
trial characteristics on 6-point Likert scales.
Results: Complete responses were received from 123 parents (52% of involved families). Twenty percent of parents
did not remember participation. Those who remembered participation reported high contentment with overall trial
participation (median 5.00), but not with follow-up (median 3.00). Most parents did not perceive any influence of
the trial on care (median 2.00) and health (median 2.43). Almost all parents reported satisfaction and pride (median
4.40), while a minority of parents reported anxiety and stress (median 1.44) or guilt (median 1.33) related to trial
participation. A relevant minority was unaware of typical trial characteristics (median 4.20; 27% being unaware).
Conclusions: Overall, parents reported positive experiences and little emotional distress long term after
participation. Future efforts to improve the practice of neonatal clinical trials should focus on ensuring effective
communication about the concept and characteristics of a clinical trial during consent discussions and on the
follow-up after the trial.
Keywords: Neonatal clinical trials, Clinical bio-ethics
Background
Many drugs are still being used off-label in neonates,
without adequate evidence [1]. Clinical trials are neces-
sary to identify better care practices, uncover useless or
harmful therapies, and reveal new knowledge gaps [2].
Balancing the interests of future patients against the in-
terests of an individual study participant remains a
difficult ethical exercise [3]. Clinical trial participants are
exposed to a treatment of which safety and efficacy are
not yet established. To deliver reliable and unbiased in-
formation, participants included in a typical clinical trial
are randomly and blindly assigned to either a study or
control (placebo) group. This concept of a clinical trial
does not necessarily serve the individual interests of a
study participant.
Clinical research in neonates has specific challenges.
Enrollment in trials in the neonatal intensive care unit
(NICU) often occurs at a moment when parents are
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overwhelmed by stress and emotions. The validity of in-
formed consent in this population has therefore been
questioned [4, 5].
There is a lack of empirical data on how parents
evaluate participation in a neonatal drug trial and on
how the trial affects their emotional well-being [6].
Currently available studies focused on smaller non-
pharmacological experimental interventions and on
the parental experience during the trial procedures
[7–11]. In the current study, we assessed the perspec-
tives and emotions of parents long term after partici-
pation in an interventional drug trial conducted in
the NICU. Parental understanding of the trial was
assessed and neonatal outcome data collected in order
to evaluate possible correlations.
Methods
Parental perspectives were evaluated through an online
questionnaire that was approved by the Ethical Commit-
tee of the University Hospitals Leuven. Formal informed
consent to participate in this study was asked in the
opening question of the questionnaire.
Setting
All five interventional clinical trials, running in the
NICU in University Hospitals Leuven between 2005
and 2015, in which neonates were exposed to a novel
treatment (novel product or novel dosing regimen)
were selected. The SMOF trial was a double-blinded,
randomized controlled clinical trial comparing a new
lipid emulsion to a conventional soy emulsion for
parenteral nutrition in preterm infants [12]. NIRTURE
was a multicenter open-label, randomized controlled
trial evaluating the effect of early insulin therapy on
mortality and sepsis in very low birth weight infants
[13]. The DORIPENEM study was a multicenter
phase I clinical trial evaluating the pharmacokinetics,
safety, and tolerance of a single dose of intravenous
infusion of doripenem in pre (term) neonates [14].
The LAIF-trial was a multicenter double-blinded,
placebo-controlled, randomized trial to test the effi-
cacy of adding recombinant bile salt-stimulated lipase
to the feeding of preterm infants to promote growth
[15]. NEOPROP was a dose-finding study to evaluate
the safety and efficacy of different doses of propofol
for sedation during semi-elective intubation [16]. The
main characteristics of the five included trials can be
retrieved from their initial publications, and are sum-
marized in Supplementary Table 1. According to Bel-
gian law, both parents have to sign the study
informed consent form. It is furthermore standard
practice in our center to discuss participation in a
clinical trial with both parents.
Recruitment
Parents of infants who participated in any of the above-
mentioned trials were eligible. Families were excluded if
they were not familiar with Dutch language or in case of
loss of parental authority. Each eligible family received
an invitation for an online survey by postal mail, along
with two unique access codes (one for each parent). Par-
ents were asked to complete the survey individually.
Non-responding families were invited a second time by
postal mail and by phone in a third attempt. If hospital
records indicated the death of the child, parents were
only contacted once. The survey was accessible from
October 2017 until March 2018.
Questionnaire
The items of this questionnaire were developed after
reviewing literature and interviewing different stake-
holders: neonatologists, psychologists, neonatal research
nurses, representatives of the Flemish preemie parent al-
liance (VVOC [17]), and a subgroup of parents of former
study participants (n = 3). Face validity of the resulting
questionnaire (comprehensibility and completeness) was
evaluated by the same stakeholder group.
The survey was formulated in Dutch, and an English
translation of the items can be found in Supplementary
Tables 2 and 3. A first part aimed to obtain background
parental information. Age-adjusted quality of life of the
child (or both children if twins) who participated in the
trial was assessed by the validated parent-reported
PEDsQL scale (Pediatric Quality of Life Inventory) [18].
In the second part, parents were asked whether they re-
membered participation in the trial. Only respondents
who answered “yes” were directed to the third and
fourth parts. The third part assessed contentment of
parents with different aspects of the trial, whether the
trial influenced care for and health of their child and
emotional consequences through a set of 52 items. Every
item was a statement on which respondents were asked
to express their level of agreement on a 6-point Likert
scale ranging from one (strong disagreement) to six
(strong agreement). Finally, a fourth part inquired
awareness on five characteristics of the clinical trial in
which they participated. A brief, lay term, explanation of
equipoise, the possibility of adverse events, placebo or
control groups, blinding, and randomization, was given.
Parents indicated if they were aware of these characteris-
tics (one item), and whether knowing this causes any
distress (three items). Parents were only directed to the
items relevant for the specific trial they participated in.
All items of parts three and four were organized in 17
predefined scales, measuring conceptually comparable
experiences or perceptions. Cronbach’s α coefficients
were calculated to assess the scale reliability [19]. For
part three, α’s of all scales ranged from 0.757 to 0.957,
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while for part four all α’s ranged from 0.639 to 0.908, in-
dicating overall good reliability (Supplementary Table 2
and 3).
Bayley scales of infant development
All infants with a gestational age below 32 weeks, born
in the University Hospitals Leuven, are invited for neu-
rodevelopmental follow-up, with assessment of Bayley
Scales of Infant Development (BSID). Data available for
study participants was retrospectively collected. We
aimed to use measurements at a prematurity-corrected
age of 24 months; however, any assessment was consid-
ered if otherwise not available (median 23months; range
7–36 months). For most infants, BSID-II was used (96%).
The BSID-III motor scale scores were excluded; BSID-
III cognitive and language scale scores were recalculated
to BSID-II mental scale scores [20].
Data analysis
Only complete responses are included in the analysis.
All analyses were performed using SPSS (version 25,
IBM). Normality was assessed with Shapiro-Wilk-tests.
Non-normally distributed variables are described as me-
dians and quartiles, while normally distributed variables
are described by means and standard deviations (sd). For
parents of twins who both participated in the trial, we
only used the lowest value of the PedsQL and BSID-II
scale scores of both twins (“worst case scenario”). Con-
struct scale score was calculated by averaging all items
of a particular scale. For visual representation, scale
values were binned to integers. We interpreted construct
scale medians of 1–1.5, 1.5–2.5, 2.5–3.5, 3.5–4.5, 4.5–
5.5, and 5.5–6, as respectively very low, low, rather low,
rather high, high, and very high levels of the measured
construct. Remembrance of trial participation was com-
pared between sexes and trials with a X2 test. Scales
were compared across sexes and trials using Mann-
Whitney U and Kruskal-Wallis tests, respectively. Spear-
man’s ρ was calculated to study correlations with ordinal
or continuous variables such as BSID, PEDsQL, and par-
ental understanding of the trial.
Results
Respondents
A total of 194 non-bereaved and 14 bereaved families
were eligible for this study. One hundred twenty-three
(32%) non-bereaved (from 103 families; 53%) and two
bereaved parents (from two families) completed the sur-
vey (Fig. 1). Respondents were predominantly mothers
(71%), and higher education outside university was the
most common educational level. The median time since
participation in the trial was 11.5 (range 3.5–13.1) years.
All participant characteristics are given in Table 1.
Remembrance of trial participation
Twenty-five respondents (20%) did not remember par-
ticipation of their child in a clinical trial. Remembering
trial participation was not significantly correlated to sex,
age, parental education, or outcome of the child (Supple-
mentary Table 4). Surprisingly, the longer the time
period since participation in the trial, the more respon-
dents remembered participation (ρ = 0.202; p = 0.025).
Remembrance was also strongly correlated to the trial
(p = 0.016), with especially lower remembrance (61%) in
NEOPROP, the most recent clinical trial (Supplementary
Table 5).
Contentment on trial participation
Overall, parents reported high levels of contentment
with trial participation (median score 5.00; Fig. 2). Re-
spondents were also rather happy with the information
they received about the trial (median score 4.33); how-
ever, 26% of respondents somehow strongly disagreed.
The recruitment and consent procedure of the trial was
Fig. 1 Flow chart of the study. Flow chart indicates eligibility and
response rate (only considering complete responses)
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overall positively evaluated (median score 4.58). In con-
trast, the majority of parents (63%) was rather unsatis-
fied with the follow-up after the trial (median score
3.00). There were no significant correlations between
contentment and sex, education, time since trial partici-
pation, trial, BSID-II, and PedsQL (Supplementary
Table 6).
Perceived influence of the trial on care and health
None of the respondents thought that trial participation
affected the routine care for their child (median score
2.00; Fig. 2). Only one respondent thought that partici-
pation influenced the health of his child (median score
2.43). Thirty-four percent of respondents somewhat
strongly agreed that the trial was beneficial for their
child (median score 3.00), while no respondents thought
it was negative (median score 1.75). Parent-reported
quality of life of the child was negatively correlated to
the perception that participation in the trial influenced
care (p = 0.021), and tended to be negatively correlated
to the perception that it influenced health (p = 0.059;
Supplementary Table 6). Furthermore, the perception
that participation had a positive influence on care and
health was more common in participants with a lower
educational attainment (p = 0.042) and in parents of in-
fants with lower BSID-II mental scale scores (p = 0.031).
Emotional consequences of trial participation
Rather high levels of satisfaction and pride were reported
(median score 4.40; Fig. 2). Parents reported very low
levels of anxiety and distress (median score 1.44) and
guilt (median score 1.33). Parental education was nega-
tively correlated to satisfaction and pride and positively
correlated to guilt (respectively, p = 0.007 and p = 0.016;
Supplementary Table 6).
Awareness of typical trial characteristics
Most, but not all, parents were aware of the characteris-
tics of the clinical trial in which their child participated
(median score 4.20; 27% being unaware; Fig. 3). Looking
at individual characteristics, awareness was lowest for
the possibility of adverse events, followed by equipoise,
randomization, the presence of a control group, and
blinding. For all five trial characteristics, a large majority
of respondents did not feel distressed after reading a
brief explanation on the topic (medians ranging from 2
to 2.33). There was a strong negative correlation be-
tween awareness and distress for each individual charac-
teristic (p ≤ 0.001; Supplementary Table 7).
Fathers were overall more aware (p = 0.008–0.178) and
less distressed (p = 0.008–0.128) than mothers about the
characteristics of the trial (Supplementary Table 8).
Overall, awareness about typical trial characteristics
tended to be related to the trial in which the respon-
dent’s child participated (p = 0.0665). Being aware about
the characteristics of the trial was also positively corre-
lated with positive perspectives on trial participation,
and negatively to anxiety and guilt (Supplementary
Table 9).
Bereaved parents
Only two bereaved parents responded, resulting in insuf-
ficient data for this group.
Discussion
Overall, parents who remembered the trial looked back
at the participation of their child as a positive experi-
ence. They were overall contented with their participa-
tion and reported rather high levels of satisfaction and
pride and low levels of anxiety, stress, and guilt. These
findings could provide comfort to researchers, who often
Table 1 Baseline characteristics of survey respondents




Parent of twins, n (%) 50 (41)
Parent of twins that were both in trial, n (%) 24 (20)
Partner also responded to survey, n (%) 20 (16)
Age at completion of questionnaire,
mean in years (± sd)
41.8 (± 5.6)
Age at participation in study,
median in years (Q1–Q3)
31.7 (28.9–34.9)
Time since participation in study,









Lower secondary education 11 (9)
Higher secondary education 31 (25)
Higher education outside university 44 (36)
Academic education (university degree) 37 (30)
BSID-II, mean (± sd)a
Mental index 99.0 (± 18.5)
Motor index 95.8 (± 19.8)
Total PedsQL, median (Q1–Q3)a 81.7 (73.3–91.7)
Baseline characteristics of survey respondents (n = 123)
aBSID-II (Bayley scale of infant development II) or PedsQL (pediatric quality of
life scale) of the respondent’s child that participated in the trial. If both
members of a twin participated in the trial only the lowest value is reported
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doubt whether it is acceptable to burden the already dis-
tressed family of a sick newborn with recruitment for a
clinical trial [21]. Furthermore, it is reassuring that par-
ents of babies with worse outcome are equally comfort-
able with trial participation. Other studies have
previously documented comparable positive experiences
among parents of neonatal clinical trial perspectives [7–
9, 11]. The current study however is the first to evaluate
the perspectives of parents of neonates participating in
interventional pharmacological trials, with a relatively in-
vasive experimental intervention, and once the long-
term outcome is known.
Interestingly, 20% of the responding parents did not re-
member trial participation. We observed significant differ-
ences between parents participating in the five included
trials. More parents forgot participation in NIRTURE
(22%) and NEOPROP (39%) in comparison to the other 3
trials. Both NIRTURE and NEOPROP required recruit-
ment very early after birth, in often instable preterm ba-
bies. Additionally, NEOPROP involved only a very brief
investigational drug exposure, and follow-up was limited
at 12 h. We hypothesize that emotional distress at the time
of consent and during the study procedure negatively af-
fects remembrance of trial participation.
It has often been questioned whether emotionally dis-
tressed parents of sick newborns are able to give volun-
tary, competent, and informed consent for trial
participation [4, 21–24]. Overall, good levels of aware-
ness on the characteristics of the clinical trial in which
their child participated indicate that most parents in this
study (regardless of education) understood to what they
consented. These results are comparable to earlier stud-
ies with parents of pediatric study participants, [25] but
contrast qualitative work demonstrating poor under-
standing of the concept of a clinical trial and
randomization in a sample of parents of neonatal study
participants [26]. In our sample, fathers were signifi-
cantly more aware and less distressed about typical trial
characteristics. We hypothesize that mothers are more
emotionally distressed at the moment of consent and
often still bear the consequences from medical condi-
tions leading to preterm birth that also affect cognitive
functioning and possibly memory [27, 28].
Nevertheless, still, 35% and 46% of the respondents
were unaware of the uncertainty concerning the effectiv-
ity (equipoise) and safety (possible adverse events) of the
experimental intervention. Furthermore, 34% of respon-
dents perceived positive effects of the clinical trial, while
Fig. 2 Descriptive results part I. Descriptive results of the construct scales evaluating (i) contentment on trial participation, (ii) perceived influence
of the trial on care and health and (ii) emotional consequences of trial participation (n=98). Median values of construct scales are expressed on 6
point Likert scales indicating agreement from 1 (strong disagreement) to 6 (strong agreement). Color bars show relative data distribution of
binned scales (%). Cronbach’s α indicates reliability of the construct scales
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no respondents perceived negative effects. The dispro-
portional optimism regarding the beneficial effects of
trial participation due to a failure in discriminating the
goals of a trial from normal clinical care is called thera-
peutic misconception [29, 30]. Our data suggests that
parents with a lower educational attainment are more
likely to overestimate the beneficial effects of the trial
and underestimate the side effects.
Self-reported awareness of study characteristics was in
our study strongly correlated to positive perspectives on
trial participation. Researchers asking for consent should
ensure that parents capture and retain the concept of
the trial properly. Recently, professional stakeholders
and parent representatives made recommendations to
ensure effective communication in consent procedures
in this setting [31]. Alternatively, other types of consent
procedures avoiding recruitment during a stressful
period (such as antenatal consent or deferred consent)
could be explored [4, 32].
This study has some limitations. First, one has to be
careful in generalizing our findings. It is possible that our
study is biased by selection of parents at least
remembering trial participation, or having a strong opin-
ion on it. Our results on remembrance of the trial and
awareness of different trial characteristics indicate that the
perspectives of parents might also be different depending
on incidental aspects of the specific trial. We also noted
important differences between trials on remembrance of
participation. Extrapolation to trials with other specific
characteristics might be difficult. Second, it is possible that
some results are biased by social desirability, leading to a
favorable trial evaluation. A qualitative study would be
able to explore how important this aspect was, and
whether parents had truly in-depth understanding of the
concept and risks of the trial in which they participated
[26, 33]. Third, despite our focus on long-term perspec-
tives, the long recall time (median 11.5 years) might have
made it difficult to give a thought out opinion on some of
the questions in the survey. Finally, with an adapted and
less aggressive recruitment strategy, we were only able to
recruit two bereaved parents. For the perspectives of this
group, we can refer to the BRACELET study that has
shown that most bereaved parents consider the trial as ir-
relevant to their child’s death [34].
Fig. 3 Descriptive results part II . Descriptive results of the construct scales and items evaluating awareness of and distress about typical clinical trial
characteristics (n=35-71). Median values of construct scales are expressed on 6 point Likert scales indicating agreement from 1 (strong disagreement)
to 6 (strong agreement). Color bars show relative data distribution of binned scales (%). Cronbach’s α indicates reliability of the construct scales
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Conclusions
In conclusion, parents report positive perspectives and
low levels of emotional distress at long term after trial
participation of their neonate. This finding can reassure
clinicians, researchers, and review boards who worry
about the emotional effect of trial participation on par-
ents of neonates. Future efforts to improve the practices
of neonatal clinical trials should focus on ensuring ef-
fective communication of the concept, risks, and benefits
of the trial to already distressed parents. Special atten-
tion should go to mothers early after birth (that were
often less aware of study characteristics) and parents
with lower educational attainment (at risk of therapeutic
misconception).
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04787-0.
Additional file 1: Supplementary Tables 1-9.
Abbreviations
NICU: Neonatal intensive care unit; VVOC: Vlaamse Vereniging van Ouders
van Couveusekinderen (Flemish preemie parent alliance); PEDsQL: Pediatric
Quality of Life Inventory; BSID: Bayley Scale of Infant Development
Acknowledgements
We acknowledge VVOC and all parents and partners involved in the
exploratory interviews leading to the development of the survey.
Furthermore, we thank all parents that were willing to participate in the
survey.
Authors’ contributions
TS designed and performed the study and coordinated the manuscript
writing. EL was involved in data collection (surveying) and analysis. AS, SV,
and MR provided data from their former study participants and provided
advice on every step of the study. EO provided and helped with the analysis
of the BSID data. LC supervised the design of the survey instrument and
guided the statistical analysis. KA and JT guided the design and proceeding
of the study and supervised manuscript writing. All authors were involved in
drafting and critically revising the manuscript. All authors approved the final
manuscript as submitted and agree to be accountable for all aspects of the
work.
Funding
This work was performed in the context of the SafePedrug project (a project
supported by an IWT grant (SBO 130033)). IWT did not have any role in the
design, performance, or interpretation of the study.
Availability of data and materials
The anonymized dataset used and/or analyzed during the current study is
available from the corresponding author on reasonable request.
Ethics approval and consent to participate
The study was approved by the Ethical Committee of the University
Hospitals Leuven under the number s60033. The first question of the survey
asked for consent of participants, a separate question asked for consent to




The authors declare that they have no conflicts of interest to disclose.
Author details
1Department of Development and Regeneration, KULeuven, Leuven,
Belgium. 2Department of Internal Medicine and Pediatrics, UGent, Ghent,
Belgium. 3Faculty of Psychology and Educational Studies, Unit of Clinical
Psychology, KULeuven, Leuven, Belgium. 4Department of Pharmaceutical and
Pharmacological Sciences, KULeuven, Leuven, Belgium. 5Department of
Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands.
Received: 1 May 2020 Accepted: 5 October 2020
References
1. Stiers JL, Ward RM. Newborns, one of the last therapeutic orphans to be
adopted. JAMA Pediatr. 2014;168:106–8.
2. DeMauro SB, Foglia EE, Schmidt B. The ethics of neonatal research: a trialists'
perspective. Semin Fetal Neonatal Med. 2015;20(6):431–5.
3. Allmark P, Mason S, Gill AB, Megone C. Is it in a neonate's best interest to
enter a randomised controlled trial? J Med Ethics. 2001;27(2):110–3.
4. McKechnie L, Gill AB. Consent for neonatal research. Arch Dis Child Fetal
Neonatal Ed. 2006;91(5):F374–6.
5. Ballard HO, Shook LA, Desai NS, Anand KJ. Neonatal research and the
validity of informed consent obtained in the perinatal period. J Perinatol.
2004;24(7):409–15.
6. Janvier A, Farlow B. The ethics of neonatal research: an ethicist’s and a
parents’ perspective. Semin Fetal Neonatal Med. 2015;20(6):436–41.
7. Stenson BJ, Becher JC, McIntosh N. Neonatal research: the parental
perspective. Arch Dis Child Fetal Neonatal Ed. 2004;89(4):F321–3.
8. Harris DL, Weston PJ, Harding JE. Mothers of babies enrolled in a
randomized trial immediately after birth report a positive experience. J
Perinatol. 2014;34(4):280–3.
9. Ayers S, Sawyer A, During C, Rabe H. Parents report positive experiences
about enrolling babies in a cord-related clinical trial before birth. Acta
Paediatr. 2015;104(4):e164–70.
10. Bradshaw L, Sawyer A, Mitchell E, Armstrong-Buisseret L, Ayers S, Duley L.
Women’s experiences of participating in a randomised trial comparing
alternative policies for timing of cord clamping at very preterm birth: a
questionnaire study. Trials. 2019;20(1):225.
11. Cumberpatch AR, Weston PJ, Harding JE, Harris DL. Parents of babies who
participated in an invasive clinical study report a positive experience: the
Glucose in Well Babies (GLOW) study. Arch Dis Child Fetal Neonatal Ed.
2020;105(1):4–7.
12. Rayyan M, Devlieger H, Jochum F, Allegaert K. Short-term use of parenteral
nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil,
medium-chain triglycerides, and fish oil: a randomized double-blind study
in preterm infants. JPEN J Parenter Enteral Nutr. 2012;36(1 Suppl):81s–94s.
13. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, Vanhole C, Palmer CR, van
Weissenbruch M, et al. Early insulin therapy in very-low-birth-weight infants.
N Engl J Med. 2008;359(18):1873–84.
14. Cirillo I, Vaccaro N, Castaneda-Ruiz B, Redman R, Cossey V, Bradley JS, et al.
Open-label study to evaluate the single-dose pharmacokinetics, safety, and
tolerability of doripenem in infants less than 12 weeks in chronological age.
Antimicrob Agents Chemother. 2015;59(8):4742–9.
15. Casper C, Hascoet JM, Ertl T, Gadzinowski JS, Carnielli V, Rigo J, et al.
Recombinant bile salt-stimulated lipase in preterm infant feeding: a
randomized phase 3 study. PLoS One. 2016;11(5):e0156071.
16. Smits A, Thewissen L, Caicedo A, Naulaers G, Allegaert K. Propofol dose-
finding to reach optimal effect for (semi-)elective intubation in neonates. J
Pediatr. 2016;179:54–60 e9.
17. VVOC.be - Vlaamse Vereniging voor Ouders van Couveusekinderen. 2020
[Available from: https://www.vvoc.be/. Accessed 16 September 2020.
18. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the
Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy
and patient populations. Med Care. 2001;39(8):800–12.
19. JCN. Assessment of reliability. Psychometric theory. 2nd edition ed. New
York: McGraw-Hill; 1978.
20. Moore T, Johnson S, Haider S, Hennessy E, Marlow N. Relationship between
test scores using the second and third editions of the Bayley scales in
extremely preterm children. J Pediatr. 2012;160(4):553–8.
21. Shilling V, Williamson PR, Hickey H, Sowden E, Smyth RL, Young B. Processes
in recruitment to randomised controlled trials of medicines for children
(RECRUIT): a qualitative study. Health Technol Assess. 2011;15(15):1–116.
Salaets et al. Trials          (2020) 21:907 Page 7 of 8
22. Burgess E, Singhal N, Amin H, McMillan DD, Devrome H. Consent for clinical research
in the neonatal intensive care unit: a retrospective survey and a prospective study.
Arch Dis Child Fetal Neonatal Ed. 2003;88(4):F280–5 discussion F5–6.
23. Wilman E, Megone C, Oliver S, Duley L, Gyte G, Wright JM. The ethical issues
regarding consent to clinical trials with pre-term or sick neonates: a systematic
review (framework synthesis) of the empirical research. Trials. 2015;16:502.
24. Mason SA, Allmark PJ. Obtaining informed consent to neonatal randomised
controlled trials: interviews with parents and clinicians in the Euricon study.
Lancet. 2000;356(9247):2045–51.
25. Chappuy H, Doz F, Blanche S, Gentet JC, Pons G, Treluyer JM. Parental
consent in paediatric clinical research. Arch Dis Child. 2006;91(2):112–6.
26. Snowdon C, Garcia J, Elbourne D. Making sense of randomization;
responses of parents of critically ill babies to random allocation of
treatment in a clinical trial. Soc Sci Med. 1997;45(9):1337–55.
27. Ionio C, Colombo C, Brazzoduro V, Mascheroni E, Confalonieri E, Castoldi F,
et al. Mothers and fathers in NICU: the impact of preterm birth on parental
distress. Eur J Psychol. 2016;12(4):604–21.
28. Kurosaki H, Nakahata K, Donishi T, Shiro M, Ino K, Terada M, et al. Effects of
perinatal blood pressure on maternal brain functional connectivity. PLoS
One. 2018;13(8):e0203067.
29. McConville P. Presuming patient autonomy in the face of therapeutic
misconception. Bioethics. 2017;31(9):711–5.
30. Woods S, Hagger LE, McCormack P. Therapeutic misconception: hope, trust
and misconception in paediatric research. Health Care Anal. 2014;22(1):3–21.
31. Neyro V, Elie V, Thiele N, Jacqz-Aigrain E. Clinical trials in neonates: how to
optimise informed consent and decision making? A European Delphi survey
of parent representatives and clinicians. PLoS One. 2018;13(6):e0198097.
32. McCarthy KN, Ryan NC, O'Shea DT, Doran K, Greene R, Livingstone V, et al.
Parental opinion of consent in neonatal research. Arch Dis Child Fetal
Neonatal Ed. 2019;104(4):F409–f14.
33. Harvey M, Nongena P, Edwards D, Redshaw M. 'We knew it was a totally at
random thing': parents' experiences of being part of a neonatal trial. Trials.
2017;18(1):361.
34. Snowdon C, Brocklehurst P, Tasker R, Ward Platt M, Harvey S, Elbourne D.
Death, bereavement and randomised controlled trials (BRACELET): a
methodological study of policy and practice in neonatal and paediatric
intensive care trials. Health Technol Assess. 2014;18(42):1–410.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Salaets et al. Trials          (2020) 21:907 Page 8 of 8
